NCT04245085: ABC-lung

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Completed Phase 2 Last updated 8 January 2025

What this trial tests

Phase 2 trial testing Atezolizumab in EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC in 95 participants. Completed in 22 July 2024.

Timeline

29 September 2020

Primary endpoint
22 July 2024

22 July 2024

Quick facts

Lead sponsor	ETOP IBCSG Partners Foundation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	95
Start date	29 September 2020
Primary completion	22 July 2024
Estimated completion	22 July 2024
Sites	18 locations across Germany, South Korea, Switzerland, Singapore, Spain

Drugs / interventions tested

• Atezolizumab
• Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
• Carboplatin
• Paclitaxel — full drug profile →
• Pemetrexed — full drug profile →

Conditions studied

• EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC — all drugs for EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC →

Sponsor

ETOP IBCSG Partners Foundation

Who can join

Adults 18 to 99, any sex, with EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR mutations after failure of standard EGFR tyrosine kinase inhibitors (TKIs).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Immunotherapy in non-small cell lung cancer: Update and new insights.
   Mielgo-Rubio X, Uribelarrea EA, Cortés LQ, Moyano MS. · · 2021 · cited 55× · PMID 34104805 · DOI 10.18053/jctres.07.202101.001
2. Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.
   Tian W, Cao C, Shu L, Wu F. · · 2020 · cited 34× · PMID 33262610 · DOI 10.2147/ott.s276150
3. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.
   Ma L, Diao B, Huang Z, Wang B, et al · · 2021 · cited 27× · PMID 34699691 · DOI 10.1002/cac2.12229
4. [Research Progress of Anti-angiogenic Agents Combined with Immunotherapy 
in Patients with Advanced Non-small Cell Lung Cancer].
   Wang J, Peng W, Jiang M, Wu L. · · 2021 · cited 2× · PMID 33819970 · DOI 10.3779/j.issn.1009-3419.2021.101.05
5. A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
   Soo RA, Vervita K, Früh M, Cho BC, et al · · 2025 · cited 1× · PMID 40023017 · DOI 10.1016/j.lungcan.2025.108454
6. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].
   Zhang T, Li B. · · 2021 · cited 1× · PMID 33819969 · DOI 10.3779/j.issn.1009-3419.2021.101.04
7. Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions.
   Wang Z, Song Y, Wang A, Liu B. · · 2026 · PMID 42100320 · DOI 10.3389/fphar.2026.1795614
8. Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer.
   Le X, Popat S, Heymach JV, West H, et al · · 2026 · PMID 41604816 · DOI 10.1016/j.esmoop.2025.106027